FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3119123076> ?p ?o ?g. }

• W3119123076 endingPage "173850" @default.
• W3119123076 startingPage "173850" @default.
• W3119123076 abstract "Cancer continues to be the second leading cause of death worldwide. Discovery of novel therapeutic agents has crucial importance for improvement of our medical management capabilities. Dysregulation of the MET receptor tyrosine kinase pathway plays an important role in cancer progression, making this receptor an attractive molecular target for anticancer drug discovery. In this study, twenty-seven 3,4-dihydropyrimidin-2(1H)-one C5 amide derivatives were synthesized and their cancer cell growth inhibitory activity was examined against MCF-7, HT-29 and MOLT-4 cells and also NIH/3T3 non-cancer cells by MTT assay. The antiproliferative effect of the most potent derivatives were tested against MET-dependent EBC-1 and MKN-45, lung and gastric cancer cell lines, respectively. MET kinase inhibition was measured by a Homogenous Time Resolved Fluorescence (HTRF) Assay. The influence of the test compounds on cell cycle was examined by RNase/PI flow cytometric assay. A number of compounds exhibited considerable antiproliferative effects against breast and colon cancer and leukemia cell lines, relatively sparing non-cancer cells. Some derivatives bearing benzothiazolyl carboxamide moiety at C5 position (15, 21, 23, 31, and 37) showed the highest activities with IC50 values as low as 10.9 μM. These compounds showed antiproliferative effects also against MET-amplified cells and dose-dependently inhibited MET kinase activity. They also induced G0/G1 cell cycle arrest at lower doses and apoptosis at higher doses. Molecular docking and dynamics simulation studies confirmed the interaction of compound 23 with the active site of the MET receptor. These findings demonstrate that 3,4-dihydropyrimidin-2(1H)-one analogues may represent promising targeted anticancer agents." @default.
• W3119123076 created "2021-01-18" @default.
• W3119123076 creator A5015660152 @default.
• W3119123076 creator A5018678718 @default.
• W3119123076 creator A5022910316 @default.
• W3119123076 creator A5023364723 @default.
• W3119123076 creator A5025014256 @default.
• W3119123076 creator A5032620524 @default.
• W3119123076 creator A5091349162 @default.
• W3119123076 date "2021-03-01" @default.
• W3119123076 modified "2023-10-10" @default.
• W3119123076 title "Antiproliferative effect, alteration of cancer cell cycle progression and potential MET kinase inhibition induced by 3,4-dihydropyrimidin-2(1H)-one C5 amide derivatives" @default.
• W3119123076 cites W1929646883 @default.
• W3119123076 cites W1965273220 @default.
• W3119123076 cites W1969002470 @default.
• W3119123076 cites W1991053537 @default.
• W3119123076 cites W1995402931 @default.
• W3119123076 cites W1999237841 @default.
• W3119123076 cites W2012949016 @default.
• W3119123076 cites W2016968824 @default.
• W3119123076 cites W2026596433 @default.
• W3119123076 cites W2026714025 @default.
• W3119123076 cites W2029178312 @default.
• W3119123076 cites W2031041310 @default.
• W3119123076 cites W2038295353 @default.
• W3119123076 cites W2040228024 @default.
• W3119123076 cites W2050456292 @default.
• W3119123076 cites W2059988098 @default.
• W3119123076 cites W2068303069 @default.
• W3119123076 cites W2088791119 @default.
• W3119123076 cites W2094234842 @default.
• W3119123076 cites W2102512629 @default.
• W3119123076 cites W2127909665 @default.
• W3119123076 cites W2134688843 @default.
• W3119123076 cites W2135732933 @default.
• W3119123076 cites W2146767272 @default.
• W3119123076 cites W2152580268 @default.
• W3119123076 cites W2169678694 @default.
• W3119123076 cites W2171528230 @default.
• W3119123076 cites W2322143219 @default.
• W3119123076 cites W2339824543 @default.
• W3119123076 cites W2402371473 @default.
• W3119123076 cites W2412633191 @default.
• W3119123076 cites W2518905728 @default.
• W3119123076 cites W2593026599 @default.
• W3119123076 cites W2740942201 @default.
• W3119123076 cites W2746820070 @default.
• W3119123076 cites W2762401006 @default.
• W3119123076 cites W2767891136 @default.
• W3119123076 cites W2772913881 @default.
• W3119123076 cites W2889646458 @default.
• W3119123076 cites W2890522709 @default.
• W3119123076 cites W2900458515 @default.
• W3119123076 cites W2913265314 @default.
• W3119123076 cites W2921963909 @default.
• W3119123076 cites W2942882997 @default.
• W3119123076 cites W2943044765 @default.
• W3119123076 cites W2944789624 @default.
• W3119123076 cites W2973058706 @default.
• W3119123076 cites W2981643996 @default.
• W3119123076 cites W2989908940 @default.
• W3119123076 cites W3007610278 @default.
• W3119123076 cites W3021706537 @default.
• W3119123076 cites W3033128777 @default.
• W3119123076 cites W3035138898 @default.
• W3119123076 doi "https://doi.org/10.1016/j.ejphar.2021.173850" @default.
• W3119123076 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33428899" @default.
• W3119123076 hasPublicationYear "2021" @default.
• W3119123076 type Work @default.
• W3119123076 sameAs 3119123076 @default.
• W3119123076 citedByCount "12" @default.
• W3119123076 countsByYear W31191230762021 @default.
• W3119123076 countsByYear W31191230762022 @default.
• W3119123076 countsByYear W31191230762023 @default.
• W3119123076 crossrefType "journal-article" @default.
• W3119123076 hasAuthorship W3119123076A5015660152 @default.
• W3119123076 hasAuthorship W3119123076A5018678718 @default.
• W3119123076 hasAuthorship W3119123076A5022910316 @default.
• W3119123076 hasAuthorship W3119123076A5023364723 @default.
• W3119123076 hasAuthorship W3119123076A5025014256 @default.
• W3119123076 hasAuthorship W3119123076A5032620524 @default.
• W3119123076 hasAuthorship W3119123076A5091349162 @default.
• W3119123076 hasConcept C101544691 @default.
• W3119123076 hasConcept C105696609 @default.
• W3119123076 hasConcept C121608353 @default.
• W3119123076 hasConcept C126322002 @default.
• W3119123076 hasConcept C170493617 @default.
• W3119123076 hasConcept C184235292 @default.
• W3119123076 hasConcept C185592680 @default.
• W3119123076 hasConcept C190283241 @default.
• W3119123076 hasConcept C2779707156 @default.
• W3119123076 hasConcept C2780783641 @default.
• W3119123076 hasConcept C29537977 @default.
• W3119123076 hasConcept C42362537 @default.
• W3119123076 hasConcept C502942594 @default.
• W3119123076 hasConcept C54355233 @default.
• W3119123076 hasConcept C55493867 @default.
• W3119123076 hasConcept C62112901 @default.

• next